Physician
Oncology
Dr. John C. Araujo, MD
|
|
Give Review
John C. Araujo is an expert in the field of Oncology. He graduated from Loyola University Chicago Stritch School of Medicine. John C. Araujo is a published physician as well. He has 23 publications published. The latest was: Human herpesvirus 6A ts suppresses both transformation by H-ras and transcription by the H-ras and human immunodeficiency virus type 1 promoters. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
- Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy.
- Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate Cancer.
- Src signaling pathways in prostate Cancer.
- PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in Cancer.
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate Cancer (READY): a randomised, double-blind phase 3 trial.
- Marine- and plant-derived É-3 fatty acids differentially regulate prostate Cancer cell proliferation.
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer.
- Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate Cancer.
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma.
- Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma.
- Personalized oncology through integrative high-throughput sequencing: a pilot study.
- Dasatinib combined with docetaxel for castration-resistant prostate Cancer: Results from a phase 1-2 study.
- Neuroendocrine prostate Cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene e...
- Dasatinib inhibits both osteoclast activation and prostate Cancer PC-3-cell-induced osteoclast formation.
- Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic Renal cell carcinoma.
- Targeting SRC family kinases inhibits growth and lymph node metastases of prostate Cancer in an orthotopic nude mouse model.
- The lack of predictors for rapid progression in prostate Cancer patients receiving sipuleucel-T.
- Human herpesvirus 6A ts suppresses both transformation by H-ras and transcription by the H-ras and human immunodeficiency virus type 1 promoters.
- Targeting Src signaling in metastatic bone Disease.
- Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid Tumors.
- Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Schools
Loyola University of Chicago Stritch School of Medicine
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Dartmouth-Hitchcock Medical Center -
Loyola University Chicago Stritch School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1801995741 | |
| NPPES Provider LastName | ARAUJO | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 595.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 25.0 | |
| Percent Opioid Claims | 4.2 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1801995741 |
| Last Name Of The Provider | ARAUJO |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Scott E. Woodman, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jeri Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joan M. Bull, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Celyne Bueno-Hume, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheridan M. Diaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shan Guo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Michael Wang |